PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'University of Plymouth, Plymouth, Devon, UK.\', \'The Vaccine Group, Ltd, Plymouth, Devon, UK.\', \'Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.\', \'University Hospitals Plymouth NHS Trust, Plymouth, Devon, UK.\', \'The Leicester School of Pharmacy, De Montfort University, Leicester, UK.\', \'Manchester Cancer Research Centre, University of Manchester, Manchester, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3851/IMP3368
?:doi
?:hasPublicationType
?:journal
  • Antiviral therapy
is ?:pmid of
?:pmid
?:pmid
  • 32744511
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.958
?:rankingScore_hIndex
  • 77
?:title
  • Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32744511>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32744511>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all